Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective (Nat Rev Cardiol. 2022 May;19(5):314-331)
Abstract |
The lungs are the primary target of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection, with severe hypoxia being the cause of death in the most critical cases.
Coronavirus disease 2019 (COVID-19) is extremely heterogeneous in terms of severity, clinical
phenotype and, importantly, global distribution. Although the majority of affected patients
recover from the acute infection, many continue to suffer from late sequelae affecting various
organs, including the lungs. The role of the pulmonary vascular system during the acute and
chronic stages of COVID-19 has not been adequately studied. A thorough understanding of the
origins and dynamic behaviour of the SARS-CoV-2 virus and the potential causes of heterogeneity
in COVID-19 is essential for anticipating and treating the disease, in both the acute and the
chronic stages, including the development of chronic pulmonary hypertension. Both COVID-19
and chronic pulmonary hypertension have assumed global dimensions, with potential
complex interactions. In this Review, we present an update on the origins and behaviour of the
SARS-CoV-2 virus and discuss the potential causes of the heterogeneity of COVID-19. In addition,
we summarize the pathobiology of COVID-19, with an emphasis on the role of the pulmonary
vasculature, both in the acute stage and in terms of the potential for developing chronic pulmonary
hypertension. We hope that the information presented in this Review will help in the development
of strategies for the prevention and treatment of the continuing COVID-19 pandemic